Brain Cancer - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：137頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Brain Cancer - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Brain Cancer - Pipeline Review, H1 2014’, provides an overview of the Brain Cancer’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Brain Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Cancer and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Brain Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Brain Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Brain Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Brain Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Brain Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Brain Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Brain Cancer - Pipeline Review, H1 2014’, provides an overview of the Brain Cancer’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Brain Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Cancer and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Brain Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Brain Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Brain Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Brain Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Brain Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Brain Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Brain Cancer Overview 10
Therapeutics Development 11
Pipeline Products for Brain Cancer - Overview 11
Pipeline Products for Brain Cancer - Comparative Analysis 12
Brain Cancer - Therapeutics under Development by Companies 13
Brain Cancer - Therapeutics under Investigation by Universities/Institutes 16
Brain Cancer - Pipeline Products Glance 18
Clinical Stage Products 18
Early Stage Products 19
Brain Cancer - Products under Development by Companies 20
Brain Cancer - Products under Investigation by Universities/Institutes 22
Brain Cancer - Companies Involved in Therapeutics Development 23
Neuralstem, Inc. 23
Basilea Pharmaceutica AG 24
Bionomics Limited 25
Critical Outcome Technologies Inc. 26
Prana Biotechnology Limited 27
e-Therapeutics plc 28
AngioChem Inc. 29
Merrimack Pharmaceuticals, Inc. 30
Stemline Therapeutics, Inc. 31
TVAX Biomedical, Inc. 32
Kinex Pharmaceuticals, LLC 33
to-BBB technologies BV 34
Nuvilex, Inc. 35
DEKK-TEC, Inc. 36
TAU Therapeutics, LLC 37
EGEN, Inc. 38
CureFAKtor Pharmaceuticals. LLC 39
Immune Pharmaceuticals, Inc. 40
Oncology Research International Limited 41
Brain Cancer - Therapeutics Assessment 42
Assessment by Monotherapy Products 42
Assessment by Target 43
Assessment by Mechanism of Action 46
Assessment by Route of Administration 49
Assessment by Molecule Type 51
Drug Profiles 53
verubulin - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
TVI-Brain-1 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
2B3-101 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
pritumumab - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
dexanabinol - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
DM-CHOC-PEN - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
MDNA-55 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
KX-02 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
COTI-2 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
BAL-27862 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
irinotecan sucrosofate liposomal - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
SL-302 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
BNC-105 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
ANG-1007 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
EGEN-001 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
ANG-1009 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
TTL-1177 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
CFAK-C4 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
NSI-566 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
KX-02 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
CFAKY-15 - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
PBT-519 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
JRP-890 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
JRP-980 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
STE-301 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
STE-401 - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
Cancer Vaccine - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
Triaryl NADPH Oxidase Inhibitor - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
STE-101 - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
ONC-201 - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
ORIL-007 - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
Methoxynaphthylfenoterol - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
MSC/dTRAIL - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
SL-301 - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
Cannabidiol For Pancreatic Cancer And Brain Cancer - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
Brain Cancer Program - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
Halistatin-3 - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
Brain Cancer - Recent Pipeline Updates 104
Brain Cancer - Dormant Projects 124
Brain Cancer - Discontinued Products 126
Brain Cancer - Product Development Milestones 127
Featured News & Press Releases 127
Jan 07, 2014: e-Therapeutics provides update on ETS2101 phase I trial in brain cancer 127
Dec 16, 2013: Positive Phase 2 Results from Agenus’ Brain Cancer Vaccine Published in Neuro-Oncology 127
Nov 25, 2013: NewGen Therapeutics Reports Potent Anticancer Activity for Targeted Brain Cancer Drug, NT-113 129
Oct 21, 2013: Angiochem Initiates Phase 2 Clinical Study for Lead Drug Candidate, ANG1005, in Primary Brain Cancer 129
Sep 26, 2013: to-BBB Presents Clinical Data on Lead Product 2B3-101 130
Aug 19, 2013: to-BBB Receives IND Approval for Novel Brain Cancer Drug, 2B3-101 131
Aug 12, 2013: DelMar Pharmaceuticals Hosts Symposium at International Brain Tumor Meeting 131
Jul 08, 2013: DelMar Pharmaceuticals and Guangxi Wuzhou Pharmaceutical Announce Chinese Government Funding Award 133
Jun 11, 2013: Critical Outcome Technologies Announces Positive Preclinical Results Of Cancer Drug Candidiate COTI-2 Against p53 Gene Mutations 133
Jun 03, 2013: Progenitor Cell Therapy Enters Into Manufacturing Agreement With ImmunoCellular Therapeutics For Dendritic Cell Vaccines Targeting Brain And Other Cancers 135
Appendix 136
Methodology 136
Coverage 136
Secondary Research 136
Primary Research 136
Expert Panel Validation 136
Contact Us 137
Disclaimer 137
List of Tables
Number of Products under Development for Brain Cancer, H1 2014 11
Number of Products under Development for Brain Cancer - Comparative Analysis, H1 2014 12
Number of Products under Development by Companies, H1 2014 14
Number of Products under Development by Companies, H1 2014 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H1 2014 17
Comparative Analysis by Clinical Stage Development, H1 2014 18
Comparative Analysis by Early Stage Development, H1 2014 19
Products under Development by Companies, H1 2014 20
Products under Development by Companies, H1 2014 (Contd..1) 21
Products under Investigation by Universities/Institutes, H1 2014 22
Brain Cancer - Pipeline by Neuralstem, Inc., H1 2014 23
Brain Cancer - Pipeline by Basilea Pharmaceutica AG, H1 2014 24
Brain Cancer - Pipeline by Bionomics Limited, H1 2014 25
Brain Cancer - Pipeline by Critical Outcome Technologies Inc., H1 2014 26
Brain Cancer - Pipeline by Prana Biotechnology Limited, H1 2014 27
Brain Cancer - Pipeline by e-Therapeutics plc, H1 2014 28
Brain Cancer - Pipeline by AngioChem Inc., H1 2014 29
Brain Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2014 30
Brain Cancer - Pipeline by Stemline Therapeutics, Inc., H1 2014 31
Brain Cancer - Pipeline by TVAX Biomedical, Inc., H1 2014 32
Brain Cancer - Pipeline by Kinex Pharmaceuticals, LLC, H1 2014 33
Brain Cancer - Pipeline by to-BBB technologies BV, H1 2014 34
Brain Cancer - Pipeline by Nuvilex, Inc., H1 2014 35
Brain Cancer - Pipeline by DEKK-TEC, Inc., H1 2014 36
Brain Cancer - Pipeline by TAU Therapeutics, LLC, H1 2014 37
Brain Cancer - Pipeline by EGEN, Inc., H1 2014 38
Brain Cancer - Pipeline by CureFAKtor Pharmaceuticals. LLC, H1 2014 39
Brain Cancer - Pipeline by Immune Pharmaceuticals, Inc., H1 2014 40
Brain Cancer - Pipeline by Oncology Research International Limited, H1 2014 41
Assessment by Monotherapy Products, H1 2014 42
Number of Products by Stage and Target, H1 2014 45
Number of Products by Stage and Mechanism of Action, H1 2014 48
Number of Products by Stage and Route of Administration, H1 2014 50
Number of Products by Stage and Molecule Type, H1 2014 52
Brain Cancer Therapeutics - Recent Pipeline Updates, H1 2014 104
Brain Cancer - Dormant Projects, H1 2014 124
Brain Cancer - Dormant Projects (Contd..1), H1 2014 125
Brain Cancer - Discontinued Products, H1 2014 126
List of Figures
Number of Products under Development for Brain Cancer, H1 2014 11
Number of Products under Development for Brain Cancer - Comparative Analysis, H1 2014 12
Number of Products under Development by Companies, H1 2014 13
Number of Products under Investigation by Universities/Institutes, H1 2014 16
Comparative Analysis by Clinical Stage Development, H1 2014 18
Comparative Analysis by Early Stage Products, H1 2014 19
Assessment by Monotherapy Products, H1 2014 42
Number of Products by Top 10 Target, H1 2014 43
Number of Products by Stage and Top 10 Target, H1 2014 44
Number of Products by Top 10 Mechanism of Action, H1 2014 46
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 47
Number of Products by Top 10 Route of Administration, H1 2014 49
Number of Products by Stage and Top 10 Route of Administration, H1 2014 50
Number of Products by Top 10 Molecule Type, H1 2014 51
Number of Products by Stage and Top 10 Molecule Type, H1 2014 52
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Brain Cancer Overview 10
Therapeutics Development 11
Pipeline Products for Brain Cancer - Overview 11
Pipeline Products for Brain Cancer - Comparative Analysis 12
Brain Cancer - Therapeutics under Development by Companies 13
Brain Cancer - Therapeutics under Investigation by Universities/Institutes 16
Brain Cancer - Pipeline Products Glance 18
Clinical Stage Products 18
Early Stage Products 19
Brain Cancer - Products under Development by Companies 20
Brain Cancer - Products under Investigation by Universities/Institutes 22
Brain Cancer - Companies Involved in Therapeutics Development 23
Neuralstem, Inc. 23
Basilea Pharmaceutica AG 24
Bionomics Limited 25
Critical Outcome Technologies Inc. 26
Prana Biotechnology Limited 27
e-Therapeutics plc 28
AngioChem Inc. 29
Merrimack Pharmaceuticals, Inc. 30
Stemline Therapeutics, Inc. 31
TVAX Biomedical, Inc. 32
Kinex Pharmaceuticals, LLC 33
to-BBB technologies BV 34
Nuvilex, Inc. 35
DEKK-TEC, Inc. 36
TAU Therapeutics, LLC 37
EGEN, Inc. 38
CureFAKtor Pharmaceuticals. LLC 39
Immune Pharmaceuticals, Inc. 40
Oncology Research International Limited 41
Brain Cancer - Therapeutics Assessment 42
Assessment by Monotherapy Products 42
Assessment by Target 43
Assessment by Mechanism of Action 46
Assessment by Route of Administration 49
Assessment by Molecule Type 51
Drug Profiles 53
verubulin - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
TVI-Brain-1 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
2B3-101 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
pritumumab - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
dexanabinol - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
DM-CHOC-PEN - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
MDNA-55 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
KX-02 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
COTI-2 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
BAL-27862 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
irinotecan sucrosofate liposomal - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
SL-302 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
BNC-105 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
ANG-1007 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
EGEN-001 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
ANG-1009 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
TTL-1177 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
CFAK-C4 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
NSI-566 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
KX-02 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
CFAKY-15 - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
PBT-519 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
JRP-890 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
JRP-980 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
STE-301 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
STE-401 - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
Cancer Vaccine - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
Triaryl NADPH Oxidase Inhibitor - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
STE-101 - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
ONC-201 - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
ORIL-007 - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
Methoxynaphthylfenoterol - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
MSC/dTRAIL - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
SL-301 - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
Cannabidiol For Pancreatic Cancer And Brain Cancer - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
Brain Cancer Program - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
Halistatin-3 - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
Brain Cancer - Recent Pipeline Updates 104
Brain Cancer - Dormant Projects 124
Brain Cancer - Discontinued Products 126
Brain Cancer - Product Development Milestones 127
Featured News & Press Releases 127
Jan 07, 2014: e-Therapeutics provides update on ETS2101 phase I trial in brain cancer 127
Dec 16, 2013: Positive Phase 2 Results from Agenus’ Brain Cancer Vaccine Published in Neuro-Oncology 127
Nov 25, 2013: NewGen Therapeutics Reports Potent Anticancer Activity for Targeted Brain Cancer Drug, NT-113 129
Oct 21, 2013: Angiochem Initiates Phase 2 Clinical Study for Lead Drug Candidate, ANG1005, in Primary Brain Cancer 129
Sep 26, 2013: to-BBB Presents Clinical Data on Lead Product 2B3-101 130
Aug 19, 2013: to-BBB Receives IND Approval for Novel Brain Cancer Drug, 2B3-101 131
Aug 12, 2013: DelMar Pharmaceuticals Hosts Symposium at International Brain Tumor Meeting 131
Jul 08, 2013: DelMar Pharmaceuticals and Guangxi Wuzhou Pharmaceutical Announce Chinese Government Funding Award 133
Jun 11, 2013: Critical Outcome Technologies Announces Positive Preclinical Results Of Cancer Drug Candidiate COTI-2 Against p53 Gene Mutations 133
Jun 03, 2013: Progenitor Cell Therapy Enters Into Manufacturing Agreement With ImmunoCellular Therapeutics For Dendritic Cell Vaccines Targeting Brain And Other Cancers 135
Appendix 136
Methodology 136
Coverage 136
Secondary Research 136
Primary Research 136
Expert Panel Validation 136
Contact Us 137
Disclaimer 137
List of Tables
Number of Products under Development for Brain Cancer, H1 2014 11
Number of Products under Development for Brain Cancer - Comparative Analysis, H1 2014 12
Number of Products under Development by Companies, H1 2014 14
Number of Products under Development by Companies, H1 2014 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H1 2014 17
Comparative Analysis by Clinical Stage Development, H1 2014 18
Comparative Analysis by Early Stage Development, H1 2014 19
Products under Development by Companies, H1 2014 20
Products under Development by Companies, H1 2014 (Contd..1) 21
Products under Investigation by Universities/Institutes, H1 2014 22
Brain Cancer - Pipeline by Neuralstem, Inc., H1 2014 23
Brain Cancer - Pipeline by Basilea Pharmaceutica AG, H1 2014 24
Brain Cancer - Pipeline by Bionomics Limited, H1 2014 25
Brain Cancer - Pipeline by Critical Outcome Technologies Inc., H1 2014 26
Brain Cancer - Pipeline by Prana Biotechnology Limited, H1 2014 27
Brain Cancer - Pipeline by e-Therapeutics plc, H1 2014 28
Brain Cancer - Pipeline by AngioChem Inc., H1 2014 29
Brain Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2014 30
Brain Cancer - Pipeline by Stemline Therapeutics, Inc., H1 2014 31
Brain Cancer - Pipeline by TVAX Biomedical, Inc., H1 2014 32
Brain Cancer - Pipeline by Kinex Pharmaceuticals, LLC, H1 2014 33
Brain Cancer - Pipeline by to-BBB technologies BV, H1 2014 34
Brain Cancer - Pipeline by Nuvilex, Inc., H1 2014 35
Brain Cancer - Pipeline by DEKK-TEC, Inc., H1 2014 36
Brain Cancer - Pipeline by TAU Therapeutics, LLC, H1 2014 37
Brain Cancer - Pipeline by EGEN, Inc., H1 2014 38
Brain Cancer - Pipeline by CureFAKtor Pharmaceuticals. LLC, H1 2014 39
Brain Cancer - Pipeline by Immune Pharmaceuticals, Inc., H1 2014 40
Brain Cancer - Pipeline by Oncology Research International Limited, H1 2014 41
Assessment by Monotherapy Products, H1 2014 42
Number of Products by Stage and Target, H1 2014 45
Number of Products by Stage and Mechanism of Action, H1 2014 48
Number of Products by Stage and Route of Administration, H1 2014 50
Number of Products by Stage and Molecule Type, H1 2014 52
Brain Cancer Therapeutics - Recent Pipeline Updates, H1 2014 104
Brain Cancer - Dormant Projects, H1 2014 124
Brain Cancer - Dormant Projects (Contd..1), H1 2014 125
Brain Cancer - Discontinued Products, H1 2014 126
List of Figures
Number of Products under Development for Brain Cancer, H1 2014 11
Number of Products under Development for Brain Cancer - Comparative Analysis, H1 2014 12
Number of Products under Development by Companies, H1 2014 13
Number of Products under Investigation by Universities/Institutes, H1 2014 16
Comparative Analysis by Clinical Stage Development, H1 2014 18
Comparative Analysis by Early Stage Products, H1 2014 19
Assessment by Monotherapy Products, H1 2014 42
Number of Products by Top 10 Target, H1 2014 43
Number of Products by Stage and Top 10 Target, H1 2014 44
Number of Products by Top 10 Mechanism of Action, H1 2014 46
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 47
Number of Products by Top 10 Route of Administration, H1 2014 49
Number of Products by Stage and Top 10 Route of Administration, H1 2014 50
Number of Products by Top 10 Molecule Type, H1 2014 51
Number of Products by Stage and Top 10 Molecule Type, H1 2014 52
